Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $2.50 | Buy | Jefferies |
9/14/2022 | $7.00 | Buy | Guggenheim |
8/15/2022 | $10.00 | Buy | Jefferies |
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
SC 13G/A - Oncology Institute, Inc. (0001799191) (Subject)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
10-Q - Oncology Institute, Inc. (0001799191) (Filer)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
8-K - Oncology Institute, Inc. (0001799191) (Filer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
4 - Oncology Institute, Inc. (0001799191) (Issuer)
CERRITOS, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ:TOI) is pleased to announce the appointment of Jordan McInerney as the new Chief Development Officer (CDO), effective April 1, 2024. In this role, Mr. McInerney will spearhead growth initiatives for The Oncology Institute across diverse markets, including cultivating new partnerships with payors, driving M&A processes for acquisition targets, and establishing MSO platforms to deliver value-based oncology care nationwide. Bringing over 15 years of healthcare leadership, McInerney most recently served as the Chief Operations Officer of HOPCo Network Solutions, a subsidiary of Hea
CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI's success as a public company. Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urolog
CERRITOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today announced that, by mutual agreement with the Board of Directors, Brad Hively will step down as Chief Executive Officer effective June 30, 2023. Dr. Daniel Virnich, the current President of TOI, will become CEO. Mr. Hively will transition to the role of Vice Chairman of the Board of Directors. Dr. Daniel Virnich has been with The Oncology Institute since 2020, initially as Chief Operating Officer before being promoted to President. He joined TOI from DaVita where he was most recently Pres
CERRITOS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2024 and updated its full year 2024 guidance. Recent Operational Highlights Include 76% increase in Dispensary segment revenue compared to prior year quarter3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings our new 2024 newly signed capitation contracts to 10Exploring strategic alternatives to maximize shareholder value Second Quarter 2024 Financia
CERRITOS, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2024 financial results after the market close on Tuesday, August 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t
CERRITOS, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI's Chief Executive Officer, will participate at the following investor conferences: Jefferies Global Healthcare ConferenceDate: June 6th, 2024Fireside Chat: 9:00am Eastern TimeTOI Participant: Daniel Virnich, M.D., MBA, Chief Executive OfficerLocation: New York City, NY Truist Securities Healthcare Disruptors & Digital Health SummitDate: June 26th, 2024Panel: 1:00pm Eastern TimeTOI Participant: Daniel Virnich, M.D., MBA, Chief Executive OfficerLocation: New York City, NY Interested inve
Jefferies resumed coverage of The Oncology Institute with a rating of Buy and set a new price target of $2.50
Guggenheim initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $7.00
Jefferies initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00
CERRITOS, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three and six months ended June 30, 2024 and updated its full year 2024 guidance. Recent Operational Highlights Include 76% increase in Dispensary segment revenue compared to prior year quarter3 new capitation contracts signed across 2 states including both medical and radiation oncology services, which brings our new 2024 newly signed capitation contracts to 10Exploring strategic alternatives to maximize shareholder value Second Quarter 2024 Financia
CERRITOS, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC ("TOI") (NASDAQ:TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its second quarter 2024 financial results after the market close on Tuesday, August 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and t
CERRITOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2024. Recent Operational Highlights Include: Successfully completed integration of first capitated risk contract direct to a health plan, and launched MSO model to enhance employed clinic locations, in the Florida market, effective January 1, 2024Partnered with MaxHealth to expand value-based care and assume clinical and financial responsibility to patients in five Florida counties7 new capitation and value-based contracts s
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family reasons, effective July 5, 2024. NIO shares dipped 8.5% to $4.4550 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 120% to $0.3870 after gaining 6% on Wednesday. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) rose 70.5% to $4.65 after gaining around 14% on Wednesday. MediWound Ltd. (NASDAQ:MDWD) shares jumped 45.6% to $21.12 after dipping around 7% on Wednesday. Koss Corporation (NASDAQ:KOSS) shares climb
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply during Wednesday's session after the company reported first-quarter financial results. Bolt Biotherapeutics posted a GAAP loss of 28 cents per share on sales of $5.30 million, according to data from Benzinga Pro. Also, Guggenheim analyst Michael Schmidt downgraded Bolt Biotherapeutics from Buy to Neutral, while Stifel analyst Stephen Willey downgraded the stock from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares dipped 34.4% to $0.8652 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers AERWINS Technologies Inc. (NASDAQ:AWIN) shares surged